CytoDyn Inc.
CYDY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CYDY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYDY
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody candidate for multiple indications, including HIV and cancer. The company faces significant financial challenges, including a substantial accumulated deficit and a going concern warning, and its future depends on securing additional capital and regulatory approval.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Feb 28, 2026.
Tracking 1 pipeline candidate · 11 clinical trials for CytoDyn Inc..
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody candidate for multiple indications, including HIV and cancer. The company faces significant financial challenges, including a substantial accumulated deficit and a going concern warning, and its future depends on securing additional capital and regulatory approval.
- CytoDyn's primary product candidate is leronlimab, a monoclonal antibody being developed for multiple indications [sec_mda].
- The company had an accumulated deficit of approximately $920.6 million as of February 28, 2026 [sec · filed 2026-04-22].
- Cash and equivalents were $15.7 million as of February 28, 2026, with a net loss of $4.7 million for the period [latest reported financials].
- The company has a going concern warning, indicating substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-22].
- CytoDyn's ability to continue operations is dependent on obtaining additional capital, completing development of leronlimab, and achieving regulatory approval [sec_mda].
What works
- CytoDyn has a product candidate, leronlimab, with potential applications in multiple indications, including HIV and cancer [sec_mda].
- The company has ongoing research and development activities for leronlimab and a new or modified longer-acting therapeutic [sec_mda].
- A one-time net income of $14.5 million in the six months ended November 30, 2024, resulted from a litigation settlement with Amarex, which temporarily improved financial results [sec_mda · as of 2026-01-09].
What to weigh
- The company has an accumulated deficit of approximately $920.6 million as of February 28, 2026, indicating significant historical losses [sec · filed 2026-04-22].
- CytoDyn has a going concern warning, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-22].
- The company's net income in the six months ended November 30, 2024, was due to a non-recurring event (litigation settlement) and does not reflect ongoing operational profitability [sec_mda · as of 2026-01-09].
- The company has negative shareholders' equity of -$116.8 million as of February 28, 2026, indicating liabilities exceed assets [latest reported financials].
From the filings
Quoted directly from source documents.
CytoDyn has a going concern warning.
“These factors, among several others, raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · April 22, 2026
The company had a significant accumulated deficit.
“The Company had an accumulated deficit of approximately $920.6 million as of February 28, 2026.”
SEC filings · April 22, 2026
The company's net income was due to a non-recurring event.
“Net income of $14.5 million in the six months ended November 30, 2024, resulted from the recovery of approximately $25.0 million in clinical expenses due to the settlement of the Company's litigation with Amarex, which is a non-recurring event.”
SEC MD&A · January 9, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to recurring losses and accumulated deficit [sec · filed 2026-04-22].
- Capital dependency — Dependence on obtaining additional operating capital to fund development and operations [sec_mda].
- Regulatory approval risk — Leronlimab requires FDA and other regulatory approvals for commercialization, which are uncertain [sec_mda].
- Negative equity — Shareholders' equity of -$116.8 million as of February 28, 2026, indicates financial distress [latest reported financials].
What to watch
- Ability to raise additional capital to fund operations and development [sec_mda].
- Progress of clinical trials and regulatory submissions for leronlimab [sec_mda].
- Any updates on the going concern status and financial restructuring [sec · filed 2026-04-22].
- Potential partnerships or licensing deals for leronlimab [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run CytoDyn Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CytoDyn Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
9.0 months
OCF -$6M · Net income -$5M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$75K
| Holder | Shares | Value |
|---|---|---|
| nbc securities, inc. | 160,000 | $44K |
| diversified trust co | 45,790 | $13K |
| next capital management llc | 25,000 | $7K |
| horizon financial services, llc | 18,200 | $5K |
| northstar asset management co | 10,000 | $3K |
| ancora advisors llc | 9,488 | $3K |
| caz investments lp | 4,000 | $1K |
| vsm wealth advisory, llc | 500 | $137 |
Governance
Frequently asked questions
What is the AI investment thesis for CytoDyn Inc.?
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody candidate for multiple indications, including HIV and cancer. The company faces significant financial challenges, including a substantial accumulated deficit and a going concern warning, and its future depends on securing additional capital and regulatory approval.
What is CytoDyn Inc.'s lead drug candidate?
CytoDyn Inc.'s most advanced tracked candidate is Leronlimab (Phase 2) for Solid Tumor, Adult; Metastatic Triple-Negative Breast Carcinoma; TNBC.
Who is the CEO of CytoDyn Inc.?
Dr. Jacob P. Lalezari M.D. is the chief executive officer of CytoDyn Inc. (CYDY).
Where is CytoDyn Inc. headquartered?
CytoDyn Inc. (CYDY) is headquartered in Vancouver, WA, United States.
What therapeutic areas does CytoDyn Inc. focus on?
CytoDyn Inc. develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.